You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neovascular

Showing 1 - 25 of 833
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neovascular Age-related Macular Degeneration Trial in Graz (Aflibercept 40 MG/ML, Faricimab 120 MG/ML)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • Aflibercept 40 MG/ML
  • Faricimab 120 MG/ML
  • Graz, Styria, Austria
    Department of Ophthalmolgy, Medical University Graz
Jul 3, 2023

Neovascular Age-related Macular Degeneration Trial (RRG001)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • (no location specified)
Nov 15, 2023

Neovascular Age-related Macular Degeneration Trial in Phoenix (CLS-AX, Aflibercept)

Recruiting
  • Neovascular Age-related Macular Degeneration
  • Phoenix, Arizona
    Retinal Research Institute, LLC
Jun 4, 2023

Neovascular Age-related Macular Degeneration Trial (Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule,

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
  • Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
  • (no location specified)
Jun 6, 2023

Neovascular Age-related Macular Degeneration Trial (PMC-403)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • (no location specified)
Jul 11, 2023

Neovascular Age-related Macular Degeneration Trial (AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • AXT107 Low Dose
  • +2 more
  • (no location specified)
May 5, 2023

Neovascular Age-related Macular Degeneration (nAMD) Trial in Abilene (OCU-10-C-110 for Injection)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration (nAMD)
  • OCU-10-C-110 for Injection
  • Abilene, Texas
    Retina Research Institute of Texas
Jun 6, 2023

Single Injection of Faricimab for nAMD With Persisting Fluid

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • Glostrup, Denmark
    Miklos Schneider
Nov 3, 2023

Neovascular Age-related Macular Degeneration (nAMD) Trial (AR-14034 SR implant lower dose, Aflibercept Injection, Sham

Not yet recruiting
  • Neovascular Age-related Macular Degeneration (nAMD)
  • AR-14034 SR implant lower dose
  • +3 more
  • (no location specified)
Mar 3, 2023

Neovascular Age-related Macular Degeneration Trial in Shanghai (LX102-C01 Injection)

Active, not recruiting
  • Neovascular Age-related Macular Degeneration
  • LX102-C01 Injection
  • Shanghai, China
    Shanghai General Hospital, Shanghai Jiao Tong University School
Apr 14, 2023

Neovascular Age-related Macular Degeneration Trial in Beijing (IBI333)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • IBI333
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Nov 28, 2022

Aflibercept Injection in Japanese Neovascular Glaucoma (NVG)

Recruiting
  • Neovascular Glaucoma
  • Aflibercept (Eylea, BAY86-5321)
  • Multiple Locations, Japan
    Many locations
Aug 17, 2022

Neovascular (Wet) Age-related Macular Degeneration (nAMD) Trial (EXG102-031)

Not yet recruiting
  • Neovascular (Wet) Age-related Macular Degeneration (nAMD)
  • EXG102-031
  • (no location specified)
Jun 13, 2023

Neovascular Age-related Macular Degeneration Trial in Seongnam-si (Probiotic Combination Cap/Tab, intravitreal Anti-VEGF

Recruiting
  • Neovascular Age-related Macular Degeneration
  • Probiotic Combination Cap/Tab
  • intravitreal Anti-VEGF injection
  • Seongnam-si, Korea, Republic of
    Seoul National University Bundang Hospital
Nov 1, 2022

Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • Aflibercept Ophthalmic
  • IBI302
  • Suzhou, Jiangsu, China
    Innovent Biologics (Suzhou) Co,Ltd.
Jul 25, 2023

Neovascular Age-related Macular Degeneration Trial in Katy, Norfolk (SKG0106)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • SKG0106
  • Katy, Texas
  • +1 more
Aug 15, 2023

Age-Related Macular Degeneration Trial in Sydney, Melbourne, Tel Aviv (VOY-101)

Recruiting
  • Age-Related Macular Degeneration
  • VOY-101
  • Sydney, New South Wales, Australia
  • +3 more
Oct 17, 2023

Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD) Trial (aflibercept 8 mg PFS)

Not yet recruiting
  • Diabetic Macular Edema (DME)
  • Neovascular Age-Related Macular Degeneration (nAMD)
  • aflibercept 8 mg PFS
  • (no location specified)
Aug 3, 2023

Age-Related Macular Degeneration Trial (KH631)

Not yet recruiting
  • Age-Related Macular Degeneration
  • (no location specified)
Dec 10, 2022

Neovascular Age-related Macular Degeneration Trial in United States (OLX10212 is a cell penetrating asymmetric small

Recruiting
  • Neovascular Age-related Macular Degeneration
  • OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
  • Santa Maria, California
  • +4 more
Jan 10, 2023

Neovascular Age Related Macular Degeneration, nAMD Trial in Wenzhou City (PDS with ranibizumab (100 mg/mL), Ranibizumab (10

Not yet recruiting
  • Neovascular Age Related Macular Degeneration
  • nAMD
  • PDS with ranibizumab (100 mg/mL)
  • Ranibizumab (10 mg/mL)
  • Wenzhou City, China
    Eye Hospital, Wenzhou Medical University
Feb 2, 2023

Russian Registry of Patients With nAMD

Terminated
  • Neovascular Age-Related Macular Degeneration
  • nAMD
  • (no location specified)
Jan 16, 2023

Age-Related Macular Degeneration Trial in Malvern, Saint Albans (BBC1501)

Not yet recruiting
  • Age-Related Macular Degeneration
  • Malvern, Victoria, Australia
  • +1 more
Apr 5, 2023

Neovascular Age-related Macular Degeneration Trial (FT-003)

Not yet recruiting
  • Neovascular Age-related Macular Degeneration
  • FT-003
  • (no location specified)
Nov 21, 2022

Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in Tehran (Aflibercept (CinnaGen Co, Iran),

Completed
  • Age-Related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Aflibercept (CinnaGen Co, Iran)
  • Aflibercept (Regeneron, USA)
  • Tehran, Iran, Islamic Republic of
    Farabi Hospital
Oct 16, 2022